Business Context and Reporting Period
This Form 6-K, filed on July 14, 2010, by Evotec SE (Evotec AG), reports the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company focused on metabolic and endocrine disorders. The transaction is expected to close in August 2010. Evotec operates as a drug discovery and early development partner with sites in Europe and Asia.
Key Financial Metrics and Transaction Details
- Acquisition Price: Up to €14 million in Evotec shares plus performance-related deferred cash payments (earn-out).
- Share Structure: €8 million (4 million shares) issued at closing; €6 million (3 million shares) conditional and held in escrow. All shares are subject to a six-month lock-up.
- Cash Requirements: Approximately €2 million for transaction costs and DeveloGen working capital.
- Liquidity Guidance: Confirmed liquidity of more than €64 million by year-end 2010.
- Revenue Outlook: Expected revenue growth of more than 15% for fiscal year 2010.
- R&D Spend: Approximately €10 million for fiscal year 2010.
Material Changes and Strategic Impact
The acquisition adds two high-value alliances to Evotec's portfolio:
- Boehringer Ingelheim Alliance: An integrated discovery alliance on small molecules for insulin resistance (Type 2 diabetes). Evotec may earn milestone payments up to €237 million for the lead compound plus royalties.
- Andromeda (Teva) Partnership: A development partnership on DiaPep277, a synthetic peptide immunomodulator for Type 1 diabetes in Phase III development. Evotec may receive royalties and significant milestones.
The deal also incorporates DeveloGen's growth factor targeting beta cell regeneration (DG770), currently in lead optimization.
Management Commentary, Risks, and Unusual Items
Management Commentary: CEO Dr. Werner Lanthaler stated the acquisition broadens Evotec's portfolio of high-value partnerships and adds substantial potential for milestone payments without assuming significant risk, as nearly half the purchase price is conditional on achieving company goals and future revenues.
Personnel Changes: Dr. Cord Dohrmann, former CEO of DeveloGen, was appointed Chief Scientific Officer and member of the Management Board, effective September 1, 2010.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding clinical trial failures, regulatory approval risks, inability to achieve collaboration benefits, and intellectual property challenges. The release of conditional shares is subject to specific company events and representations.
Investor Verification Checklist
- Verify the closing date of the DeveloGen acquisition (expected August 2010).
- Confirm the specific conditions required to release the €6 million in escrowed shares.
- Monitor the progress of the DiaPep277 Phase III trials and the Boehringer Ingelheim lead compound development.
- Review Q3 and Q4 2010 financial reports to confirm the €64 million liquidity target and >15% revenue growth.
- Assess the integration of DeveloGen's 21 employees and assets into Evotec's operations.